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A B S T R A C T
Nrf2 (NFE2L2 – nuclear factor (erythroid-derived 2)-like 2) is a transcription factor, which is repressed by in-
teraction with a redox-sensitive protein Keap1 (Kelch-like ECH-associated protein 1). Deregulation of Nrf2
transcriptional activity has been described in the pathogenesis of multiple diseases, and the Nrf2/Keap1 axis has
emerged as a crucial modulator of cellular homeostasis. Whereas the significance of Nrf2 in the modulation of
biological processes has been well established and broadly discussed in detail, the focus on Keap1 rarely goes
beyond the regulation of Nrf2 activity and redox sensing. However, recent studies and scrutinized analysis of
available data point to Keap1 as an intriguing and potent regulator of cellular function. This review aims to shed
more light on Keap1 structure, interactome, regulation and non-canonical functions, thereby enhancing its
significance in cell biology. We also intend to highlight the impact of balance between Keap1 and Nrf2 in the
maintenance of cellular homeostasis.
1. Introduction
The fundamental role of defence pathways is to integrate adaptive
cellular responses to stress events. These highly coordinated strategies
aim to counteract internal disturbances, minimise acute damage, reset
the homeostasis of the cell and sustain its survival. The Nrf2/Keap1 axis
has been recognised as a central node for a cross-talk of cellular defence
and survival pathways. Nrf2 (nuclear factor (erythroid-derived 2)–like
2) is a transcription factor, which transactivates expression of over
1000 protective genes [1,2], which comprise more than 1% of the
human genome [3]. Its transcriptional activity is mainly regulated by a
redox-sensitive repressor Keap1 (Kelch-like ECH-associated protein 1)
[4]. Many excellent reviews deeply describe the exact mechanisms of
Nrf2 regulation and its protective effects on the cellular homeostasis
(exhaustively reviewed in Ref. [5]). Recent research has been broadly
focused on the manipulation of Nrf2-Keap1 interaction, which enables
modulation of Nrf2 activity in the therapeutic approaches [6]. The role
of Keap1, however, has been attributed mainly to Nrf2 repressor
function and redox sensor. Still, thanks to its extraordinary structure
and reactivity, Keap1 undergoes numerous post-translational mod-
ifications, has a very rich interactome, and, thus, is involved in various
cellular processes. We aim to underline this atypical biological sig-
nificance of Keap1 in this review.
2. Keap1 résumé
Keap1, encoded by the KEAP1 gene, was discovered in 1999. A two-
hybrid screening assay identified it as a protein repressing Nrf2 tran-
scriptional activity, sensitive to electrophiles [4]. It is also an in-
tracellular sensor of oxidants [7]. KEAP1 evolved as a product of gene
duplication. In fish, two isoforms of keap1 gene, keap1a and keap1b, are
distinguished. During evolution, they separated, and keap1b was coe-
volving with vertebrate homologues [8,9]. Keap1 is a well-conserved
protein, sharing around 95% of sequence homology between species
(data from NCBI) and, importantly, possessing the same function
throughout the phylogenic tree among the vertebrates [10]. The En-
sembl database reports that there are 10 splicing variants of human
Keap1 gene, out of which 2 alternatively spliced transcript variants,
possessing 6 exons and 5 introns, encode the same protein isoform,
which is the full-length 624 amino acid long. Six other transcript var-
iants encode potential isoforms (116, 129, 172, 212, 213 and 279
amino acid long), which were computationally mapped (uniprot.org).
The last 2 transcript variants encode no protein. Recently 444 amino
acid long Keap1 isoform, derived from the alternative splicing variant
lacking the fourth and fifth exons, has been described in human highly-
metastatic hepatoma cells and other cell lines. This isoform is missing
the double glycine repeat (DGR, Kelch) domain, which is responsible
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for interactions with Nrf2 [11].
Keap1 is expressed widely in various cell types and tissues [4]. It is
mostly located in the perinuclear region of the cytoplasm, but also in the
nucleus, endoplasmic reticulum and inclusion bodies [12–14]. Its absolute
amount ranges between 50 000 to 300 000 molecules per cell, which
corresponds to ~1 μM concentration [15]. That makes it a moderately
abundant protein relative to another well-known repressor and a compo-
nent of E3 ubiquitin ligase Hdm2 (up to 200 000 copies) [16] or tran-
scription factors (up to 100 000 copies) [17]. It could partially explain how
it preferentially is activated by Michael addition, its usual mode of redox
activation [18]. Human Keap1 contains 27 cysteines (Table 1), which
comprise 4.33% of all amino acids, whereas the average content of cy-
steines in human proteins is 2.26% [19]. Since the median length of
coding sequences of human proteins is 375 amino acids [20], the average
cysteine content counts for 8 per protein, which means that Keap1 con-
tains over two times more cysteines than the average protein in human.
This fact is of particular significance since the cysteine proteome plays a
fundamental role in many biological functions (please refer to Ref. [21] for
more details). A large part of Keap1 cysteines is highly reactive due to
surrounding positively-charged, basic amino-acids [22]. The electrophile
compounds activating Nrf2 modify directly critical Keap1 cysteine re-
sidues by alkylation and oxidoreduction reactions [23]. They can be di-
vided into four classes, depending on Keap1 cysteine preferences [24]. It
was shown that the oxidants, such as H2O2 and HClO, might induce Keap1
transient oxidation, but its mechanism remains elusive [25]. Interestingly,
the study carried out it a zebrafish model showed that H2O2 is capable of
Nrf2 target gene (gstp1) induction in an Nrf2-dependent manner in larvae
but not in embryonic cells. Therefore, it was proposed that factors addi-
tional to Nrf2 and Keap1, absent at the embryonic stage, are required for
sensing of H2O2 [23]. Keap1 is a metalloprotein binding zinc, which
modulates the reactivity of Keap1 critical cysteines, thus influencing Nrf2-
dependent response [26]. Coordination of zinc by Keap1 may explain how
it can react with H2O2 preferentially versus most other protein cysteines
under physiological conditions [27]. The breaking of the O–O bond in
H2O2 cannot be significantly achieved under physiological conditions by
cysteine alone, even in its thiolate (S-) form, because OH- is an extremely
poor leaving group. Protonation of the leaving OH- or the proximity of a
metal, such as Zn2+, to which the OH- could bind, facilitates the oxidation
of cysteine. It is well established that Keap1 represents a sensor of en-
vironmental stress [9], creates an adaptive interface between the expo-
some and genome [21], and is a target for pharmacological modification
as it has been comprehensively reviewed in Ref. [6,7].
3. Keap1 structure
Keap1 is a member of the BTB-kelch protein family, which com-
prises about 50 members classified as Kelch-like (KLHL1-42, Keap1 is
classified as KLHL19) or Kelch, and possessing BTB domain 1-14
(KBTBD1-14). All of these proteins contain two canonical domains in
their structure: BTB (Broad-Complex, Tramtrack and Bric a brac) and
Kelch domain [28,29]. Five distinct regions can be distinguished in the
structure of Keap1: (i) the N-terminal region (NTR), position 1–49 aa,
(ii) BTB (also named poxvirus and zinc finger (POZ)) domain, position
50–179 aa, (iii) intervening region (IVR, also named BACK domain),
position 180–314 aa, (iv) double-glycine repeat (DGR, Kelch) domain,
position 327–611 aa, and (v) C-terminal region (CTR), position
612–624 aa [7], as depicted in Fig. 1A.
The BTB domain is an evolutionarily conserved motif with the
multifunctional role, including mediation of Keap1 homodimerisation,
its interactions with the Cullin-3-Rbx-1-E3 ligase complex, and sensing
electrophilic compounds, including the most potent activators of Nrf2,
the cyclic cyanoenones, and nitric oxide through a highly reactive cy-
steine residue (C151) [9,30–34]. The major determinants of the high
reactivity of this cysteine are basic amino acids, K131, R135, and K150,
and H154, localised in the spatial proximity to C151 [9,25,35]. Keap1
homodimerisation via BTB domain is required for the interaction with
Nrf2 [36], which is achieved directly by Kelch domain of Keap1 and
Neh2 domain of Nrf2 through its DLG and ETGE motifs (Fig. 1B) [37].
The IVR region (position 209–314 aa) is cysteine-rich. Two critical
cysteine residues C273 and C288 are required for the repression of Nrf2
nuclear accumulation [38,39] and responsible for sensing of alkenals
[9]. The IVR region contains the most reactive residues of Keap1 (C257,
C272, C288, and C297), which are the direct redox sensors [18]. They
are a target for pharmacological activation of this pathway as it is re-
viewed in Refs. [6,7].
The DGR domain contains six repeats of Kelch motif, which form a
six-bladed β-propeller structure. Each blade of this structure (I-VI) is
built of four-stranded antiparallel β-sheets (A-D), which enable Keap1
interactions with diverse proteins [40]. The sequences of Kelch repeats
differ between particular KLHL1-42, providing the substrate selectivity
[28]. However, some regions are conserved: DGR, present at the end βB
strand along with individual tyrosine (βC) and tryptophan (βD) re-
sidues, arbitrates hydrophobic packing between blades. Thus, the Kelch
domain is also referred to as DGR or DC (DGR and CTR) domain [41].
Those similar features enable the maintenance of overall “kelch” shape.
The vast majority of kelch domains (just as in the case of Keap1) form
six-bladed beta-propellers [29].
The X-ray structures of Kelch [40,42,43] and BTB domains [44]
have provided essential insights in their detailed structure. The spatial
organisation of all domains has been revealed by cryogenic electron
microscopy. Keap1 resembles a cherry bob, where BTB domains form a
stem, whereas IVR and Kelch domains are closely located and form the
spherical “cherry” part (for the structural details, please refer to Ref.
[45]).
Table 1
Keap1 is highly rich in cysteines. Comparison between human, mouse and rat.
Human Mouse Rat
gene KEAP1 Keap1 Keap1
aliases iNrf2, KLHL19 iNrf2, mKIAA0132 iNrf2
chromosome 19 9 8
cysteines 27 25 25
amino acids 624 624 624
Fig. 1. Keap1 structure. (A) The organisation
of Keap1 domains. NTR – N-terminal region.
BTB - Broad-Complex, Tramtrack and Bric a
brac. IVR-intervening region. DGR - double-
glycine repeat region. CTR – C-terminal region;
(B) Schematic illustration of the Keap1-Cul3-E3
ligase complex interacting with the Neh2 do-
main of Nrf2 via the DLG and ETGE motifs. Cul3
– cullin3; Rbx1 – RING box protein 1; E2 –
ubiquitin ligase with ubiquitin (yellow circles).
(For interpretation of the references to colour in
this figure legend, the reader is referred to the
Web version of this article.)
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4. Regulation of Keap1 expression, level and activity
The level and activity of Keap1 are regulated via several mechan-
isms: (i) transcriptional regulation, (ii) epigenetic modifications, (iii)
miRNAs, (iv) somatic mutations, (v) post-translational modifications,
and (vi) degradation (Fig. 2).
KEAP1 is a transcriptional target of BRD4 [46,47], SP1 [48,49], Nrf2
[50] and possibly AP2 [49]. Also, the presence of putative binding sites
for transcription factors: hepatic nuclear factor (HNF-1), signal trans-
ducer and activator of transcription-6 (STAT-6), CCAAT/enhancer-
binding protein (C/EBP), OCT1, aryl hydrocarbon receptor (Ahr)/Arnt
heterodimers, and hypoxia-inducible factor (HIF), has been identified in
murine Keap1 gene [50]. On the contrary, sirtuin 6 (Sirt6) deacetylase
was shown to decrease Keap1 transcript in cardiomyocytes. The mole-
cular mechanism of this suppression remains, however, unknown [51].
The level of Keap1 transcript is affected by differential methylation of
its promoter. Keap1 increases with age in the human lens due to de-
methylation of its promoter, which results in higher gene expression
[52]. Similar regulation is observed in diabetic conditions and in re-
sponse to several compounds like methylglyoxal (MGO) [53] or valproic
acid [54,55]. On the other hand, hypermethylation of the promoter is
observed in many types of cancers, including lung, colon, prostate and
gliomas. It also correlates with disease progression [48,49,56–59]. The
promoter hypermethylation perturbs Keap1 transcription and sig-
nificantly decreases its protein level [49,59]. Keap1 level can also be
negatively regulated by miR-7 [60], miR-24-3p [61], miR-141 [62,63],
miR-200a [64,65], miR-421 [66], miR-626 [67], and mir-873 [68].
Numerous mutations characterise the coding region of KEAP1 gene in
cancer cells [69,70]. They are associated with poor prognosis as they
promote the proliferation of cancer cells and cause resistance to che-
motherapy in different types of cancers [reviewed in Refs. [71,72]]. In-
terestingly, they are spanned uniformly across the whole gene and rarely
cause protein truncation. Instead, the mutations result in altered ability
to bind and regulate Nrf2 degradation, usually abrogating or decreasing
its binding capacity. However, there are some mutations within Keap1
which may facilitate Keap1 and Nrf2 interactions - called ‘superbinders’
(R320Q, R470C, G423V, D422 N, G186R, S243C and V155F). However,
despite strong binding and enhanced ubiquitination, Keap1 mutant dis-
ables Nrf2 degradation, leading to increased Nrf2 transcriptional activity
[73]. This group of mutants is also called ‘ANCHOR’ (Additionally NRF2-
Complexed HypomORph). Interestingly, the anchor feature relates only
to the increased interaction with Nrf2, but not with other Keap1-inter-
acting proteins, for which the relation is comparable to the wild-type.
The ANCHOR mutations stabilise Keap1 and phase-separate in a se-
questosome (SQSTM1, p62)-dependent manner [74].
Due to its reactive nature, Keap1 undergoes many post-translational
modifications, including S-nitrosation, ubiquitination, alkylation, car-
bonylation, glycosylation, S-glutathionylation, oxidation, phosphor-
ylation, succination, and sulfhydrylation. They serve as an alternative
way of non-canonical Nrf2-activation (summarised in Table 2). Cur-
iously, two of them, ubiquitination and S-nitrosation, not only modify
the Keap1 residues but are also directly dependent on Keap1 [30,75]. In
regard to ubiquitination, Keap1 is an adaptor protein for E3 ligase
complex [30–33], which ubiquitinates cellular proteins, including Nrf2
[32], IKKβ [76,77], PGAM5 [78], Miro2 [79], MCM3, SLK, MAD2L1
[80], and possibly also Myo9b [81]. Keap1 itself also undergoes ubi-
quitination, which predisposes it to proteasomal-independent de-
gradation and enables Nrf2 activation [82]. In accordance, the deubi-
quitinating enzyme USP15 negatively regulates Nrf2 through
deubiquitination of Keap1 [83]. Concerning the S-nitrosation-Keap1
cross-talk, Keap1 may undergo S-nitrosation (SNO) at C151 and C273
residues [84–86], and recently it has been recognised as a crucial reg-
ulator of this post-translational modification [75] (further described in
more detail). Keap1 also evolved as a sensor of nitric oxide [9]. Another
type of feedback regulation is observed in case of MGO, which modifies
Keap1 to form MICA (methylimidazole crosslink between proximal
cysteine and arginine residues) and functionally inactivates it [87]. At
the same time, treatment of cells with MGO induces Keap1 promoter
DNA demethylation leading to overexpression of Keap1 mRNA and
protein [88]. There are several post-translational modifications
Fig. 2. The modes of Keap1 regulation. The level and activity of Keap1 are regulated via several mechanisms: transcription factors, epigenetic modifications,
miRNAs, somatic mutations, post-translational modifications, and degradation. VA – valproic acid, MGO – methylglyoxal.
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(malonylation, palmitoylation and acetylation), which have been re-
ported, however, the exact impact on Keap1 was not fully elucidated
[101–103].
Degradation of Keap1 occurs via p62-dependent autophagy [104],
which is facilitated upon its preceding ubiquitination [82]. In basal
conditions, the half-life of Keap1 is ~13 h, whereas electrophiles, such
as tert-butylhydroquinone (tBHQ) or 1,2-naphthoquinone (1,2-NQ) can
accelerate its degradation. The half-life of modified Keap1 is shortened
to 3.4 h and 7.1 h by tBHQ and 1,2-NQ, respectively [104].
5. Keap1 interactome
Nrf2 is a hallmark interacting protein for Keap1. Many methods
were implemented to study this interaction and to establish the minimal
interacting fragment, including surface plasmon resonance [105],
fluorescence polarisation assay [106], FRET [107], and ITC [108]. They
revealed that Nrf2 binds to Keap1 in stoichiometry 1:2. Neh2 domain of
Nrf2 is recruited to Keap1 by ETGE and DLG motifs [109]. Both motifs
interact with the same residues of Keap1 dimer (DGR/Kelch), however
with different binding affinities, probably due to different acidic residue
composition. The ETGE motif has 100 times higher affinity than DLG
[43,110]. This interaction can be mimicked by 16-aa long fragment,
containing Nrf2 ETGE motif [107,111], or even 9 aa- (LDEETGEFL) or 7
aa-long (DEETGEF) sequences [105,106]). A minimal Nrf2 recognition
sequence is of 6–7 amino acids [112].
The Nrf2/Keap1 complex adopts two different conformations, se-
quentially alternating in a cycle in basal conditions [3]. The open
conformation is formed by newly synthesised Nrf2, which binds to one
Keap1 molecule of the ‘cherry bob’ Keap1 dimer via high-affinity ETGE
motif. This does not allow for Nrf2 ubiquitination and protects Nrf2
from proteasomal degradation. In the next step, low-affinity DLG motif
of Nrf2 binds to the second member of Keap1 dimer. Thus, the complex
adopts a closed conformational state, which predisposes Nrf2 for
Keap1/Cul3/E3 ligase-dependent polyubiquitination and subsequent
proteasomal degradation. The free Keap1 enters the next cycle then [3].
It is postulated that the inducers of Nrf2 activity block Nrf2/Keap1
complex in the closed conformation, but Nrf2 ubiquitination is not
feasible then, and Nrf2 remains trapped by Keap1. Therefore, transac-
tivation of Nrf2 target genes in achieved by de novo synthesised Nrf2,
rather than through the liberation of Nrf2 from Keap1 complex [3].
The majority of Keap1-binding partners contain an evolutionally
conserved ETGE motif, which is responsible for these interactions
(Fig. 3) [113,114]. Direct interaction of Keap1 with other proteins via
the non-canonical motifs, such as ELKE/ENKE, GLNLG, ARM domain,
was also found (Table 3). Binding of the ETGE-containing proteins to
Keap1 can displace Nrf2, preventing its degradation and enabling its
translocation to the nucleus and the expression of cytoprotective genes.
The interactions of Keap1 with other proteins and interaction motifs
were discovered in the pull-down assay or in high-throughput studies
and further confirmed by mutations and exchange of amino acids. Some
of the interactors were also denoted in the Spotlite database [115]. The
Keap1 interactors p62, DPP3 and Bcl-xL were also determined in cDNA
screenings based on ARE-driven transcriptional activity. Another, later
neither described nor verified in context of Nrf2, were D-site of albumin
promoter binding protein (DBP), kinesin family member 26B (KIF26B),
cAMP-responsive element-binding protein-regulated transcription
coactivator 1 (CRTC1), myeloid cell leukaemia sequence 1 (MCL1), and
splicing factor, arginine/serine-rich 10 (SFRS10) [116]. Keap1 inter-
actors verified by biochemical methods are presented in Table 3. All the
depicted proteins, similarly to Nrf2, interact with Keap1 via its Kelch
domains. The compounds disrupting the Keap1/Nrf2 interaction (e.x.
sulforaphane, tBHQ or H2O2) were shown to have no effect or to in-
crease interactions of Keap1 with its binding partners (Table 4). A
significant part of Keap1-interacting proteins is characterised by the
presence of disordered regions, which contain many acidic amino acids
[117]. Kelch domain contains multiple positively-charged residues.
Table 2
Post-translational modifications of Keap1. * - the modifications that are both mediated by Keap1 and exerted on Keap1 protein itself.
Modification Residue Increase in Nrf2 activity Reference
Ubiquitination* K39, K61, K84, K97, K108, K287, K312, K615 Yes (essential for Keap1 degradation) [82,89]
S-nitrosation* C151, C273 Yes [9,84–86]
Alkylation (itaconate) C151, C257, C273, C288, C297 Yes (modifies and lowers Keap1 level) [90]
Carbonylation C273, C288 Yes [91]
Glycosylation S104 No (crucial in mediating Nrf2
ubiquitination)
[92]
S-glutathionylation C434 Yes [93,94]
MICA (methylimidazole crosslink between proximal cysteine and
arginine residues)
MICA crosslink between C151 and R135 Yes [87]
Nitro fatty acids C38, C226, C257. C273, C288, C489 Yes [95]
Oxidation disulphide between C226 and C613; intramolecular
between C151
Yes [25,26]
Phosphorylation Y206, Y263, Y334, Yes (enabling Keap1 nuclear export) [96]
Succination C151, C288 Yes [97–99]
Sulfhydrylation C151 Yes [100]
Malonylation K131 n.d. [101]
Acetylation K131 n.d. [102]
Palmitoylation n.d. n.d. [103]
Fig. 3. Alignment of the confirmed Keap1 interaction motifs.
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Thus, such an interaction is favoured [118]. Additionally, previously
reported Keap1-interacting proteins, like myosin VIIa [119], cortactin
[120,121], RhoGAP1 [122,123], contain SH3 domains. Apart from in-
teraction with eukaryotic proteins, Keap1 was shown to interact with
Marburg virus proteins [124]. Additionally, there are also small mole-
cules that bind to the Kelch domain [125]. Mass spectrometry-identi-
fied proteins interacting with Keap1 are listed in Ref. [80,113,126,127].
6. Keap1 and NO-based regulation
Nitric oxide and reactive nitrogen species (RNS) induce Nrf2 nuclear
translocation. It is achieved due to the S-nitrosation [9,84–86] or oxi-
dative modification [25,26] of Keap1. However, the NO-related func-
tions of Keap1 go beyond its post-translational modifications, aimed at
the release of Nrf2.
A sensor of nitric oxide in Keap1 is cysteine C151 located in the BTB
domain, which interestingly emerged in coincidence with the expansion
of NOS family of proteins. NO sensing capacity of C151 is dependent on
the presence of basic amino acids K131, R135 and K150, which spa-
tially are present in the direct vicinity of C151. Perceiving of NO is
accomplished by S-nitrosation of this cysteine residue [9]. However,
Keap1 is not only a sensor of NO and RNS. Recently, it has also been
recognised as a crucial modulator of S-nitrosation [75]. S-nitrosation it
is an oxidative chemical reaction that generates a nitroso group on a
cysteine thiol. Throughout years, the mechanism of formation of the
nitrosothiol in the biological systems was elusive and thought to be
non-enzymatic. Especially that such a reaction would require the for-
mation of an intermediate NO+ [152], and the kinetics of such me-
chanisms raises constraints in in vivo conditions [153,154]. Keap1 di-
rectly interacts with nitric oxide synthase (NOS) and transnitrosating
protein GAPDH (glyceraldehyde 3-phospho dehydrogenase) to govern
S-nitrosation in mammalian cells. Depriving the cells of any protein of
this complex inhibits protein S-nitrosation [75]. Keap1/GAPDH/NOS
enzymatic complex resembles the bacterial one, which comprises SNO
synthase (Hcp), transnitrosylase GAPDH and NarGHI, as NO source
[155]. It suggests that Keap1 can be a mammalian SNO synthase. It
could be speculated that NO sensing by C151 and the requirement of
positively charged amino acids for this process could account for such
enzymatic activity of Keap1. Importantly, Keap1-related S-nitrosation
of NOX4 has a fundamental significance in endothelial cells (ECs),
protecting them from oxidative damage and apoptosis in the absence of
Nrf2. Moreover, S-nitrosation determines EC fate, balancing between
premature senescence and cellular death [75].
7. Keap1 in cytoskeleton regulation
Just upon discovery of Keap1 as Nrf2-interactor [4], the similarity
of Keap1 to Drosophila Kelch protein was raised. Kelch is required to
organise the ovarian ring canal cytoskeleton through F-actin binding
and cross-linking [156]. Keap1 was shown to colocalise with a variety
of both integrin and cadherin-based adhesion assemblies [119,157].
Subsequently, due to the resemblance to Drosophila Kelch protein, the
interaction between Keap1 and actin was investigated. Keap1 coloca-
lises and interacts with actin via its DGR domain. Disruption of actin
leads to the release of Nrf2 from Keap1 interaction and its nuclear
translocation [128]. Keap1 is present in focal adhesions and adherent
junctions, but not in stress fibres [158]. It stabilises F-actin and restricts
focal adhesion turnout. Additionally, its overexpression weakens the
Table 3
Proteins interacting with Keap1, verified by biochemical methods. The location of interacting amino acids was shown for human (h) proteins. Presence of the
interacting motif was also verified in mouse (m) and rat (r) proteins based on the sequence search. X – unspecified amino acid.
Protein name and symbol Function Motif interacting with Keap1 Reference
Actin Cytoskeleton n.d. [128]
BPTF/FAC1 Chromatin regulation n.d. [129]
Cdk20 Cell cycle 25ETGE28, h m r [130]
DPP3 Protein degradation 480ETGE483, h m r [113,116,131]
EGFR Growth factor signalling n.d. [96]
Fam129b Apoptosis suppression, signalling 708DLG710, h
718ETGE721, h m r
[132]
Gankyrin Proteasome subunit 21ELKE24, h m r
201ENKE204, h m r
[133]
GAPDH Metabolism n.d. [75]
HBXIP Amino-acid sensing, viral response 110GLNLG115, h [134]
HSP90 Protein folding n.d. [135]
IKKB Regulation of NFkB signaling 36ETGE39, h [76,77]
KPNA6 (importin α7) Nuclear import of Keap1 ARM domain [136]
MAD2A Cell division 92ESGE96, h m [137]
MCM3 DNA replication 387ETGE390, h m r [80,138]
Nestin Intermediate filament 1414ESGE1417, h m r
DLG - predicted
[127]
NOS3 Production of nitric oxide n.d. [75]
p65 Inflammation n.d. [139]
PALB2 DNA repair 91ETGE94, h m r [140,141]
PGAM5 Necrosis 79ESGE82, h m r [78,79,142,143]
PIDD Apoptosis n.d. [126]
PTMA Chromatin remodeling 43ENGE46, h m r [13,144,145]
RelA-associated inhibitor (iASPP) p53 regulator 239DLT241, h [146]
RMP Gene transcription regulation EXXE, h m [147]
p62 Autophagy 349STGE352, h m r (phosphorylated) [148,149]
WTX, AMER1 Regulation of Wnt signaling pathway 288ETGE291, h [73,150]
Table 4
The effect of compounds activating Nrf2, tBHQ, sulforaphane and H2O2, on the
interaction of Keap1 with its binding partners.
Protein name and symbol tBHQ sulforaphane H2O2 Reference
DPP3 – – increase [131]
gankyrin no effect no effect increase [133]
MCM3 no effect no effect – [80]
PALB2 no effect – no effect [140]
PGAM2 – increase no effect [142,151]
iASPP increase – – [146]
RMP – – increase [147]
WTX no effect – – [150]
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migratory capacity of cells and triggers thick stress fibres formation due
to RhoA overactivity. The latter is caused by the enhanced Myo9b de-
gradation [81]. Furthermore, Keap1 regulates actin organisation,
through associations with actin-regulatory proteins, such as myosin
VIIa [119]. More complex regulation was reported in case of cortactin,
which subcellular localisation is regulated by Keap1 binding [121].
Finally, Keap1 leads to the overabundance of RhoGAP1, the protein
regulating Cdc42 activity. It impairs podosome formation and disrupts
actin rearrangements, thus preventing endothelial cell migration and
angiogenesis [123]. Keap1 may also interact with the other components
of the cytoskeleton, tubulin [159], intermediate filament lamin [131]
and nestin [127]. However, the functional significance of these inter-
actions remains unknown.
8. Keap1 in proteostasis
The role of Nrf2 in proteostasis is mostly attributed to the tran-
scriptional regulation of the ubiquitin-proteasome system and autop-
hagy [reviewed in Ref. [160,161]]. Keap1 is an essential component of
Rbx1-E3-ubiquitin complex, which marks various proteins for de-
gradation, including Nrf2 [32], but also IKKβ [76,77], PGAM5 [78],
Miro2 [79], MCM3, SLK, MAD2L1 [80], and possibly Myo9b [81].
Additionally, Keap1 interacts with DPP3, which participates in the
hydrolysis of peptides formed during proteasomal degradation
[113,116,131]. However, there is no data on how Keap1 affects DPP3
enzymatic activity. Keap1 was reported to assist in ubiquitin aggregate
clearance through autophagy, where it interacts with p62 and LC3
[162]. In response to selective autophagy, it relocalises to inclusion
bodies following interaction with p62 [12]. Keap1 colocalises with p62
in puncta to foster its degradation [148,162–164]. The interaction be-
tween Keap1 and p62 occurs following phosphorylation of STGE motif
of p62, which can be executed by mTORC1 [165] or TAK1 [166]. Thus,
an increase in the negative charge of this sequence enables interaction
with positively charged residues of the Kelch domain of Keap1. The
binding affinity of this pair is similar to the one observed for the DLG
motif of Nrf2 and Kelch [149]. The interaction between p62 and Keap1
is enhanced when p62 undergoes phase separation (and appears as
puncta) driven by cytoplasmatic DAXX (death-associated protein 6)
[167]. Importantly, mutation in the KIR domain of p62, which abro-
gates the interaction of Keap1 with p62, has been associated with
amyotrophic lateral sclerosis (ALS) [168]. High-throughput data also
indicate for Keap1 interaction with essential autophagy regulator Atg5
[169]. Co-immunoprecipitation revealed direct interaction of Keap1
with proteasomal subunits PSMD2, PSMD4 and segregase Vcp/p97
[74], the latter, interestingly, had been previously reported to nega-
tively regulate Nrf2 stability [154].
9. Keap1 at the mitochondrial interface
There are some contradictory data on the localisation of Keap1 in
mitochondria, depending on the experimental setup and method used
[14]. However, there is a growing body of evidence indicating the
presence of Keap1 in the proximity of mitochondria, where it interacts
with mitochondrial protein PGAM5 [78,79,143]. This interaction te-
thers Nrf2 at the mitochondria, thus abrogating its transcriptional ac-
tivity [143]. However, a decrease either in Nrf2 or PGAM5 causes im-
pairment of retrograde mitochondrial signalling, due to hyperactivity of
Keap1-Cul3 complex and enhanced degradation of Miro2 [79]. More-
over, during an elevated generation of oxidants, Keap1/PGAM5 med-
iates caspase-independent cell death, called ‘oxeiptosis’ [142]. Con-
versely, Keap1 is crucial for the maintenance of proper mitochondrial
homeostasis, as p62 recruits it to mitochondria, and together with
Rbx1, mediates mitochondrial ubiquitination, thus, preventing the
formation of dysfunctional megamitochondria and mitigating non-
alcoholic fatty liver disease [170].
10. Keap1 and cell cycle progression
Apart from the cytoplasmatic localisation, Keap1 is also present in the
nucleus [131,136]. The Kelch domain-derived interaction with importin
α7/karyopherin α6 (KPNA6) is required for the nuclear import of Keap1,
which is crucial in the fine-tuning of the antioxidant response [136].
Similarly, p65 interacts with Keap1 and promotes its nuclear transloca-
tion [139]. These nucleus-related functions of Keap1 were investigated
mainly in the context of Nrf2 activation. However, Keap1 may also be a
crucial regulator of cell cycle progression, independently of Nrf2. Re-
cently, Keap1 was shown to negatively regulate endothelial cell pro-
liferation and induce senescence in those cells [75,123]. Moreover,
Keap1 knockout mice fail to properly execute the S-phase of the cell cycle
during liver regeneration [171]. This impairment was associated with
deregulation among cell-cycle mediators and mitogenic pathways. Keap1
knockout mice were also characterised by better genome integrity and
stability, possibly due to increased expression of Rad51 [171]. BRCA1
and PALB2 are essential regulators of DNA damage response, also
through the recruitment of Rad51. Notably, Keap1, through sequestra-
tion of PALB2, impedes the cell-cycle dependent BRCA1-PALB2 inter-
action [141]. Furthermore, more in-depth studies revealed that Keap1
interacting motif in PALB2 is central to PALB2-BRCA1 complex forma-
tion and facilitation of homologous recombination in G1 cells. Keap1
recruits CRL3 ubiquitination complex to PALB2. The ubiquitin moiety on
lysine 20 of PALB2 suppresses its interaction with BRCA1. Finally, in-
activation of Keap1 leads to the formation of stable BRCA1-PALB2-
BRCA2 complex in both G1 and S phases [141].
MCM3 (DNA replication licensing factor, mini-chromosome main-
tenance protein), involved in DNA replication, interacts similarly to
MCM7 with Keap1-Cul3 complex in cell-cycle dependent manner.
However, this interaction does not lead to MCM degradation. Instead, it
regulates MCM complex dynamics [80]. Keap1, together with MCM3
and MCMBP, were shown to form a ternary complex. The interaction
with MCMBP was also reported in high throughput study [172]. In-
terestingly, Keap1 may interact with Cdk20 [130], Chd6 [131], Cdc34
[173], Sass6 and many other [174]. Keap1 forms also complex with
ProTα [13,144,145], which regulates the compaction state of chro-
matin. However, this interaction was not studied in the context of
proliferation and cell cycle progression.
11. Keap1 repression and the significance of Nrf2/Keap1 balance
The unique structure of Keap1 and the resulting diversity of inter-
acting proteins may suggest that the interplay between Keap1 and its
interactome should be tightly controlled. The function of Keap1 as an
Nrf2 repressor has been very well established; the issue of Keap1 re-
pression, however, has been beyond the research mainstream until
now. Recent papers have recognised that the presence of unrestrained
Keap1 is detrimental for cellular homeostasis [75,79,123] and empha-
sised the role of Nrf2 as the repressor of Keap1 [75,123], which im-
plicates that Nrf2 and Keap1 mutually inhibit each other. Nrf2-depleted
cells exhibited substantial deregulation of mitochondrial homeostasis
due to the Keap1-mediated degradation of Miro2 [79]. The function of
endothelial cells devoid of Nrf2 is aggravated due to the overabundance
of unrestrained Keap1, which stabilises RhoGAP1 and potentiates pro-
tein S-nitrosation, inhibiting angiogenesis and evoking premature se-
nescence of ECs [75,123]. The role of Nrf2 as Keap1 repressor is further
supported by the phenotype of Nrf2 transcriptional knockout mice, in
which the sequence coding the DNA binding domain has been disrupted
by LacZ, resulting in the formation of fusion protein N-terminal Nrf2-β-
gal. Unless challenged by detrimental factors, these animals develop
well and do not exhibit abnormal phenotype. It is likely achieved by the
presence of the Neh2 domain in these animals, capable of Keap1
binding [123]. The clinical significance of Nrf2/Keap1 imbalance can
be implicated in age-related diseases [reviewed in Ref. [175]]. Keap1 is
reported to increase during ageing [176] or in the models of premature
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senescence [75]. However, the exact role of Keap1, in contrast to that of
Nrf2, in ageing has not been addressed yet.
Keap1 inactivation, thus defined by Nrf2 hyperactivity, is char-
acterised by multiple disorders, including hyperkeratosis of the digestive
tract [177], bone hypoplasia [178], abnormal kidney development and
function [179,180], and pancreatic atrophy [181]. Nrf2 serial activation
was also associated with hyperproliferation of keratinocytes and patho-
genesis of psoriasis [182]. Additionally, such cells (keratinocytes with
Nrf2 overactivity) are featured by sebaceous gland enlargement and se-
borrhea, together with thickening and hyperkeratosis of hair follicle in-
fundibula [183]. Furthermore, when mice were expressing a con-
stitutively active Nrf2 (caNrf2) mutant in hepatocytes, liver regeneration
was impaired due to delayed proliferation and enhanced apoptosis
[184]. Finally, recently it was demonstrated in adult flies, that while mild
Nrf2 activation extended lifespan, a high Nrf2 expression level led to
developmental lethality or, after inducible activation, it altered mi-
tochondrial bioenergetics, led to the onset of diabetes type 1 hallmarks
and ageing acceleration [185]. The adverse effects of Nrf2 hyperactivity
often result from the overabundance of its target genes or through me-
tabolic reprogramming [186]. Accordingly, Keap1 loss promotes Kras-
driven lung cancer and results in dependence on glutaminolysis
[187,188] and consequently on exogenously delivered non-essential
amino-acids (NEAA) [189]. Detrimental effects of Nrf2 hyperactivity
have also been described in 4 cases of human mutations in NFE2L2,
which disable the binding of Nrf2 to Keap1. The patients exhibited de-
velopmental delay, failure to thrive, immunodeficiency, leukoencepha-
lopathy, and hypohomocysteinaemia [190]. Remarkably, as described
above, the lack of either Nrf2 [75,79,123] or Keap1 [177] results in
detrimental effects for the cells and organisms. Dysfunction of cells de-
void of Nrf2, exhibiting impaired angiogenic potential and migration,
senescence onset and increased S-nitrosation of proteins in case of en-
dothelial cells and aberrant mitochondrial trafficking in case of retinal
pigment epithelial cells, can be fully rescued by concomitant deletion of
Keap1 [75,79,123]. In accordance, detrimental effects of Keap1
knockout, hyperkeratosis and constriction of oesophagus accounting for
juvenile lethality of these mice, are reversed in Nrf2/Keap1 double
knockout animals [177]. These results evidence that Nrf2/Keap1 balance
is crucial to maintain cellular homeostasis.
The physiological and clinical relevance of Nrf2 hyperactivity
models, Keap1-null [177] and caNrf2 [184] mice, might be question-
able, taking into consideration that human Keap1 deficiency has not
been reported so far and in caNrf2 mice Neh2-deficient caNrf2 is driven
by a powerful CMV promoter [184]. To address this issue, we compared
the fold change of Nrf2 target gene expression in these mice, patients
with mutations within Neh2 domain of Nrf2 [190] and human tumours
with loss of NFE2L2 exon 2 [191]. The expression of target genes in
caNrf2 mouse is usually increased by ~10-fold up to ~100-fold [184],
in Keap1-null mouse by ~10-30-fold up to ~400-fold [180], in Keap1
floxed mouse, which revealed the hypomorphism of floxed Keap1 allele
and milder phenotype than Keap1-null animals, by ~10-fold [192].
Expression of Nrf2 target genes in human cells isolated from patients
with Neh2 mutations was increased usually by ~2-fold up to ~60-fold
[190], while in human tumour samples deficient in exon 2 of NFE2L2
by ~2-fold up to ~30-fold [191]. These limitations might be relevant,
taking into account ‘the hormetic characteristics’ of Nrf2 activity [193],
which also supports the significance of Nrf2/Keap1 balance.
12. Concluding remarks
The function of Keap1 as an Nrf2 repressor has been established
exceptionally well and in detail. However, Keap1 is not only a repressor
of Nrf2. The non-canonical functions of Keap1 should be explored
further, for example, in the context of age-related dysfunctions, when
an imbalance between Nrf2 and Keap1 occurs. Moreover, these atypical
functions of Keap1 and the role of Nrf2 as a Keap1 repressing protein
should be taken into consideration during data interpretation.
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